Literature DB >> 20833339

Clinical and molecular genetics of parathyroid neoplasms.

John M Sharretts1, William F Simonds.   

Abstract

Primary hyperparathyroidism (HPT) results from the excessive secretion of parathyroid hormone from parathyroid tumours. While most HPT is sporadic, it is associated with a familial syndrome in a minority of cases. The study of these syndromes has helped define the pathophysiology of both familial and sporadic parathyroid neoplasms. Investigation of kindred with multiple endocrine neoplasia type 1 (MEN1) and the hyperparathyroidism-jaw tumour syndrome (HPT-JT) led to the discovery of the tumour suppressor genes MEN1 and HRPT2. We now recognise that somatic mutations in MEN1 and HRPT2 tumour suppressor genes are frequent events in sporadic parathyroid adenomas and carcinomas, respectively. Parathyroid tumours in the MEN2A syndrome result from mutational activation of the RET oncogene. The CCND1/PRAD1 oncogene was discovered by analysis of sporadic parathyroid tumours. Studies of familial isolated HPT and analysis of chromosomal loss and gain in parathyroid tumours suggest that other genes relevant to parathyroid neoplasia await identification. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833339      PMCID: PMC2939004          DOI: 10.1016/j.beem.2010.01.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  99 in total

Review 1.  Hyperparathyroidism.

Authors:  William D Fraser
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

2.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

3.  A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia.

Authors:  Steven A Lietman; Yardena Tenenbaum-Rakover; Tjin Shing Jap; Wu Yi-Chi; Yang De-Ming; Changlin Ding; Najat Kussiny; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2009-09-29       Impact factor: 5.958

4.  Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation.

Authors:  Roger Y W Shih; Sarah Fackler; Stephen Maturo; Mark W True; Joseph Brennan; David Wells
Journal:  Endocr Pract       Date:  2009 Sep-Oct       Impact factor: 3.443

Review 5.  Molecular alterations in hereditary and sporadic thyroid and parathyroid diseases.

Authors:  Jennifer L Hunt
Journal:  Adv Anat Pathol       Date:  2009-01       Impact factor: 3.875

Review 6.  Molecular genetics of parathyroid disease.

Authors:  Gunnar Westin; Peyman Björklund; Göran Akerström
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

7.  Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.

Authors:  O Vierimaa; A Villablanca; A Alimov; M Georgitsi; A Raitila; P Vahteristo; C Larsson; A Ruokonen; E Eloranta; T M L Ebeling; J Ignatius; L A Aaltonen; J Leisti; P I Salmela
Journal:  J Endocrinol Invest       Date:  2009-03-26       Impact factor: 4.256

8.  Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas.

Authors:  Koen M A Dreijerink; Radhika A Varier; Rick van Nuland; Roel Broekhuizen; Gerlof D Valk; Jacqueline E van der Wal; Cornelis J M Lips; J Alain Kummer; H Th Marc Timmers
Journal:  Mol Cell Endocrinol       Date:  2009-09-01       Impact factor: 4.102

Review 9.  Parafibromin--functional insights.

Authors:  P J Newey; M R Bowl; R V Thakker
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

10.  Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.

Authors:  Brian Harding; Manuel C Lemos; Anita A C Reed; Gerard V Walls; Jeshmi Jeyabalan; Michael R Bowl; Hilda Tateossian; Nicky Sullivan; Tertius Hough; William D Fraser; Olaf Ansorge; Michael T Cheeseman; Rajesh V Thakker
Journal:  Endocr Relat Cancer       Date:  2009-07-20       Impact factor: 5.678

View more
  35 in total

1.  [Disseminated osteolytic lesions in a 28-year-old refugee].

Authors:  T Karrasch; H D Walmrath; M Kampschulte; D Steiner; W Seeger; W Padberg; U Sibelius; S Gattenlöhner; A Schäffler
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

2.  Primary hyperparathyroidism: just how 'primary' is it really?

Authors:  Richard Quinton; Stephen G Ball; John Sayer; Simon H S Pearce
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

3.  A rare case of symptomatic hyperparathyroidism in an elderly patient with dual pathology.

Authors:  Shahab Khan; Harpreet Sekhon; Radu Mihai; Stephanie Jenkins
Journal:  AME Case Rep       Date:  2018-05-15

4.  Identification of a germline mutation in the HRPT2 gene in a Chinese family with parathyroid carcinomas.

Authors:  Mei Zhang; Qin Li; Lili Zhang; Rongzhan Fu; Yulong Wang; Shouhua Chen; Kai Yuan; He Gu; Yazhou Cui
Journal:  Intractable Rare Dis Res       Date:  2012-02

5.  EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms.

Authors:  E Sanpaolo; M Miroballo; S Corbetta; C Verdelli; F Baorda; T Balsamo; P Graziano; F P Fabrizio; L Cinque; A Scillitani; L A Muscarella; Vito Guarnieri
Journal:  Endocrine       Date:  2016-02-15       Impact factor: 3.633

6.  MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.

Authors:  Vince Kornél Grolmusz; Katalin Borka; Annamária Kövesdi; Kinga Németh; Katalin Balogh; Csaba Dékány; András Kiss; Anna Szentpéteri; Beatrix Sármán; Anikó Somogyi; Éva Csajbók; Zsuzsanna Valkusz; Miklós Tóth; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

7.  Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.

Authors:  Erin F Wolff; Micah J Hill; William F Simonds; James H Segars
Journal:  Fertil Steril       Date:  2012-09-08       Impact factor: 7.329

Review 8.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

9.  A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.

Authors:  Virginia Bellido; Ihintza Larrañaga; Maite Guimón; Rafael Martinez-Conde; Asier Eguia; Gustavo Perez de Nanclares; Luis Castaño; Sonia Gaztambide
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

10.  CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.

Authors:  Vito Guarnieri; Claudia Battista; Lucia Anna Muscarella; Michele Bisceglia; Danilo de Martino; Filomena Baorda; Evaristo Maiello; Leonardo D'Agruma; Iacopo Chiodini; Celeste Clemente; Salvatore Minisola; Elisabetta Romagnoli; Sabrina Corbetta; Raffaella Viti; Cristina Eller-Vainicher; Anna Spada; Michela Iacobellis; Nazzarena Malavolta; Massimo Carella; Lucie Canaff; Geoffrey N Hendy; David E C Cole; Alfredo Scillitani
Journal:  Cell Oncol (Dordr)       Date:  2012-09-18       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.